Concord Biotech

Concord Biotech EBIT per Share

The EBIT per Share of Concord Biotech (CONCORDBIO.NS) as of Oct 18, 2026 is 32.97 INR. In the previous year, EBIT per Share was 57.54 INR — a change of -42.70% (lower).

EBIT per Share

32.97INR

YoY

-42.70%

Last updated:

EBIT per Share of Concord Biotech is 2026 32.97 INR. EBIT per Share of Concord Biotech was 2025 57.54 INR. It decreases by -42.70% lower compared to the previous year.

The Concord Biotech EBIT per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Share
Date
EBIT per Share
Jan 1, 2023
49.48 INR
Jan 1, 2024
49.84 INR
Jan 1, 2025
57.54 INR
Jan 1, 2026
32.97 INR
Jan 1, 2027 (e)
43.85 INR
Jan 1, 2028 (e)
57.05 INR
Jan 1, 2029 (e)
70.92 INR
Jan 1, 2031 (e)
0.00 INR
The Concord Biotech EBIT per Share history
YEAREBIT per ShareYoY
est0.00INR-100.00%
est70.92INR+24.31%
est57.05INR+30.11%
est43.85INR+32.98%
32.97INR-42.70%
57.54INR+15.45%
49.84INR+0.74%
49.48INR+24.28%
39.81INR-3.15%
41.11INR+37.91%
29.81INR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Concord Biotech Stock analysis

What does Concord Biotech do? Concord Biotech Ltd is a pharmaceutical company headquartered in Ahmedabad, India. It operates in the Health Care sector with a focus on Pharmaceuticals. The company went public via an IPO on August 18, 2023. Concord Biotech develops and manufactures active pharmaceutical ingredients (APIs) using fermentation and semi-synthetic processes. It produces finished formulations and APIs for therapeutic areas including immunosuppressants, anti-bacterial, oncology, and anti-fungal treatments. The company's API portfolio includes Mycophenolate Mofetil, Cyclosporine, Vancomycin Hydrochloride, and others. It also has a pipeline of API products under development such as Polymyxin B and Fidaxomicin. Concord Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Concord Biotech stock

EBIT per Share of Concord Biotech is 32.97 INR in 2026.

EBIT per Share of Concord Biotech changed from 57.54 INR to 32.97 INR, representing a -42.70% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Share Concord Biotech since 2006 – with annual values, charts, and detailed analysis.

EBIT per Share measures operating profit allocated to each outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Concord Biotech

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Concord Biotech